Search

Your search keyword '"Schepisi, Giuseppe"' showing total 90 results
Start Over Author "Schepisi, Giuseppe"
90 results on '"Schepisi, Giuseppe"'

51. Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy

Author

Cursano, Maria Concetta, primary, Kopf, Barbara, additional, Scarpi, Emanuela, additional, Menna, Cecilia, additional, Casadei, Chiara, additional, Schepisi, Giuseppe, additional, Lolli, Cristian, additional, Altavilla, Amelia, additional, Gallà, Valentina, additional, Santini, Daniele, additional, Tonini, Giuseppe, additional, Chovanec, Michal, additional, Mego, Michal, additional, and De Giorgi, Ugo, additional

Published
2020
Full Text
View/download PDF

52. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

Author

Altavilla, Amelia, primary, Casadei, Chiara, additional, Lolli, Cristian, additional, Menna, Cecilia, additional, Ravaglia, Giorgia, additional, Gurioli, Giorgia, additional, Farolfi, Alberto, additional, Brighi, Nicole, additional, Conteduca, Vincenza, additional, Burgio, Salvatore Luca, additional, Schepisi, Giuseppe, additional, Rossi, Lorena, additional, Gargiulo, Stefania, additional, Lisotti, Ivana, additional, and De Giorgi, Ugo, additional

Published
2020
Full Text
View/download PDF

53. Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy

Author

Conteduca, Vincenza, primary, Caffo, Orazio, additional, Scarpi, Emanuela, additional, Sepe, Pierangela, additional, Galli, Luca, additional, Fratino, Lucia, additional, Maines, Francesca, additional, Chiuri, Vincenzo Emanuele, additional, Santoni, Matteo, additional, Zanardi, Elisa, additional, Massari, Francesco, additional, Toma, Ilaria, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Sbrana, Andrea, additional, Kinspergher, Stefania, additional, Cursano, Maria Concetta, additional, Casadei, Chiara, additional, Modonesi, Caterina, additional, Santini, Daniele, additional, Procopio, Giuseppe, additional, and De Giorgi, Ugo, additional

Published
2020
Full Text
View/download PDF

54. Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial.

Author

De Giorgi, Ugo, primary, Schepisi, Giuseppe, additional, Gurioli, Giorgia, additional, Pisano, Carmela, additional, Basso, Umberto, additional, Lolli, Cristian, additional, Petracci, Elisabetta, additional, Casadei, Chiara, additional, Cecere, Sabrina Chiara, additional, Attademo, Laura, additional, Clemente, Alberto, additional, Zampiga, Valentina, additional, Galla, Valentina, additional, Cangini, Ilaria, additional, Di Napoli, Marilena, additional, Valmorri, Linda, additional, and Pignata, Sandro, additional

Published
2020
Full Text
View/download PDF

55. Use of plasma androgen receptor (AR) testing to optimize docetaxel chemotherapy in castration-resistant prostate cancer (CRPC): A multicenter biomarker study.

Author

Conteduca, Vincenza, primary, Castro, Elena, additional, Wetterskog, Daniel, additional, Scarpi, Emanuela, additional, Romero-Laorden, Nuria, additional, Gurioli, Giorgia, additional, Jayaram, Anuradha, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Wingate, Anna, additional, Casadei, Chiara, additional, Lozano, Rebeca, additional, Brighi, Nicole, additional, Aragon, Isabel, additional, Marín-Aguilera, Mercedes, additional, González-Billalabeitia, Enrique, additional, Mellado, Begona, additional, Olmos, David, additional, Attard, Gerhardt, additional, and De Giorgi, Ugo, additional

Published
2020
Full Text
View/download PDF

56. Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.

Author

Gurioli, Giorgia, primary, Conteduca, Vincenza, additional, Basso, Umberto, additional, Fornarini, Giuseppe, additional, Mosca, Alessandra, additional, Nicodemo, Maurizio, additional, Banna, Giuseppe Luigi, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Gargiulo, Stefania, additional, Altavilla, Amelia, additional, Testoni, Sara, additional, Scarpi, Emanuela, additional, and De Giorgi, Ugo, additional

Published
2020
Full Text
View/download PDF

57. Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration‐resistant cancer patients.

Author

Conteduca, Vincenza, Scarpi, Emanuela, Wetterskog, Daniel, Brighi, Nicole, Ferroni, Fabio, Rossi, Alice, Romanel, Alessandro, Gurioli, Giorgia, Bleve, Sara, Gianni, Caterina, Schepisi, Giuseppe, Lolli, Cristian, Cortesi, Pietro, Matteucci, Federica, Barone, Domenico, Paganelli, Giovanni, Demichelis, Francesca, Beltran, Himisha, Attard, Gerhardt, and De Giorgi, Ugo

Subjects
CASTRATION-resistant prostate cancer, THROMBOEMBOLISM, PROSTATE cancer, CANCER patients, METASTASIS, ANDROGEN deprivation therapy, DNA
Abstract

Cancer is a risk factor for venous thromboembolism (VTE). Plasma tumor DNA (ptDNA) is an independent predictor of outcome in metastatic castration‐resistant prostate cancer (mCRPC). We aimed to investigate the association between ptDNA and VTE in mCRPC. This prospective biomarker study included 180 mCRPC patients treated with abiraterone and enzalutamide from April 2013 to December 2018. We excluded patients with a previous VTE history and/or ongoing anticoagulation therapy. Targeted next‐generation sequencing was performed to determine ptDNA fraction from pretreatment plasma samples. VTE risk based on survival analysis was performed using cumulative incidence function and estimating sub‐distributional hazard ratio (SHR). At a median follow‐up of 58 months (range 0.5‐111.0), we observed 21 patients who experienced VTE with a cumulative incidence at 12 months of 17.1% (95% confidence interval [CI] 10.3‐23.9). Elevated ptDNA, visceral metastasis, prior chemotherapy and lactate dehydrogenase (LDH) were significantly associated with higher VTE incidence compared to patients with no thrombosis (12‐month estimate, 18.6% vs 3.5%, P =.0003; 44.4% vs 14.8%, P =.015; 24.7% vs 4.5%, P =.006; and 30.0% vs 13.5%, P =.05, respectively). In the multivariate analysis including ptDNA level, visceral metastases, number of lesions and serum LDH, high ptDNA fraction was the only independent factor associated with the risk of thrombosis (HR 5.78, 95% CI 1.63‐20.44, P =.006). These results first suggest that baseline ptDNA fraction in mCRPC patients treated with abiraterone or enzalutamide may be associated with increased VTE risk. These patients may be followed‐up more closely for the VTE risk, and the need for a primary thromboprophylaxis should be taken into account in mCRPC with elevated ptDNA. What's new? Patients with cancer are at increased risk for venous thromboembolism (VTE). Here, the authors test the correlation between plasma tumor DNA (ptDNA) and VTE in patients with metastatic castration‐resistant prostate cancer. In prostate cancer, the concentration of ptDNA prior to treatment can predict clinical outcome. This study enrolled 180 patients who were receiving androgen deprivation therapy. The patients with high ptDNA had a greater incidence of VTE than those with low ptDNA. These results suggest that ptDNA could be a useful tool for assessing VTE risk and improving long‐term survival. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

58. Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome.

Author

Conteduca, Vincenza, Scarpi, Emanuela, Caroli, Paola, Lolli, Cristian, Gurioli, Giorgia, Brighi, Nicole, Poti, Giulia, Farolfi, Alberto, Altavilla, Amelia, Schepisi, Giuseppe, Matteucci, Federica, Paganelli, Giovanni, and De Giorgi, Ugo

Abstract

Plasma tumour DNA (ptDNA) is a potential early noninvasive biomarker of treatment outcome in metastatic castration‐resistant prostate cancer (mCRPC). Herein, we investigated whether pretreatment ptDNA levels reflect metabolic tumour burden in mCRPC and better predict treatment outcome in combination with functional imaging. Targeted next‐generation sequencing was performed to estimate the ptDNA fraction from 102 mCRPC patients receiving abiraterone or enzalutamide. The maximum standardized uptake value (SUVmax), total lesion activity (TLA) and metabolic tumour volume (MTV) were evaluated on 18F‐fluorocholine positron emission tomography/computed tomography. We assessed a Weibull multiple regression model to determine the combined impact of clinical, molecular and imaging characteristics on overall survival (OS) and progression‐free survival (PFS), and to obtain prognostic scores. A significant association was seen between ptDNA and SUVmax, MTV and TLA. For survival analysis, patients were randomly allocated into a training (n = 68) and a validation (n = 34) set. In the training set, multivariable analyses showed that ptDNA, MTV and serum lactate dehydrogenase together with visceral metastasis were independent predictors of both OS and PFS. Prognostic scores were generated, with the identification of three groups of patients with significantly different median OS (29.2, 15.9 and 8.7 months) and PFS (13.3, 7.7 and 3.2 months) probabilities. The differences in median survival between risk groups were confirmed in the validation cohort for both OS and PFS. In our study, we showed that integrating plasma DNA analysis with functional imaging may improve prognostic risk stratification and treatment selection in mCRPC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

59. Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors

Author

Schepisi, Giuseppe, Brighi, Nicole, Cursano, Maria Concetta, Gurioli, Giorgia, Ravaglia, Giorgia, Altavilla, Amelia, Burgio, Salvatore Luca, Testoni, Sara, Menna, Cecilia, Farolfi, Alberto, Casadei, Chiara, Tonini, Giuseppe, Santini, Daniele, and De Giorgi, Ugo

Subjects
Article Subject
Abstract

Immunotherapy represents the new era of cancer treatment because of its promising results in various cancer types. In urological tumors, the use of the immune-checkpoint inhibitors (ICIs) is increasingly spreading. Although not all patients and not all diseases respond equally well to immunotherapy, there is an increasing need to find predictive markers of response to ICIs. Patient- and tumor-related factors may be involved in primary and secondary resistance to immunotherapy: tumor-derived protein and cytokines, tumor mutational burden, and patient performance status and comorbidities can condition tumor response to ICIs. Recently, some of these factors have been evaluated as potential biomarkers of response, with conflicting results. To date, the expression of programmed death-ligand 1 (PD-L1) and the presence of deficient mismatch repair (dMMR) in tumor tissue are the only biomarkers capable of guiding the clinician’s decision in urothelial cancer and prostate cancer, respectively. In this review, we performed a comprehensive search of the main publications on biomarkers that are predictive of response to ICIs in urological cancers. Our aim was to understand whether existing data have the potential to drive clinical decision-making in the near future.

Published
2019
Full Text
View/download PDF

61. Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis

Author

Conteduca, Vincenza, primary, Scarpi, Emanuela, additional, Matteucci, Federica, additional, Caroli, Paola, additional, Ravaglia, Giorgia, additional, Fantini, Lorenzo, additional, Gurioli, Giorgia, additional, Schepisi, Giuseppe, additional, Wetterskog, Daniel, additional, Menna, Cecilia, additional, Burgio, Salvatore Luca, additional, Lolli, Cristian, additional, Paganelli, Giovanni, additional, Attard, Gerhardt, additional, and De Giorgi, Ugo, additional

Published
2019
Full Text
View/download PDF

62. Plasma Androgen Receptor in Prostate Cancer

Author

Conteduca, Vincenza, primary, Gurioli, Giorgia, additional, Brighi, Nicole, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Casadei, Chiara, additional, Burgio, Salvatore Luca, additional, Gargiulo, Stefania, additional, Ravaglia, Giorgia, additional, Rossi, Lorena, additional, Altavilla, Amelia, additional, Farolfi, Alberto, additional, Menna, Cecilia, additional, Colangione, Sarah Pia, additional, Pulvirenti, Mario, additional, Romeo, Antonino, additional, and De Giorgi, Ugo, additional

Published
2019
Full Text
View/download PDF

63. Testosterone levels and androgen receptor copy number variations in castration‐resistant prostate cancer treated with abiraterone or enzalutamide

Author

Lolli, Cristian, primary, Lisi, Delia, additional, Conteduca, Vincenza, additional, Gurioli, Giorgia, additional, Scarpi, Emanuela, additional, Schepisi, Giuseppe, additional, Ravaglia, Giorgia, additional, Menna, Cecilia, additional, Farolfi, Alberto, additional, Altavilla, Amelia, additional, Burgio, Salvatore Luca, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, and Giorgi, Ugo, additional

Published
2019
Full Text
View/download PDF

64. Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support

Author

De Padova, Silvia, primary, Casadei, Chiara, additional, Berardi, Alejandra, additional, Bertelli, Tatiana, additional, Filograna, Alessia, additional, Cursano, Maria Concetta, additional, Menna, Cecilia, additional, Burgio, Salvatore Luca, additional, Altavilla, Amelia, additional, Schepisi, Giuseppe, additional, Prati, Sabrina, additional, Montalti, Sandra, additional, Chovanec, Michal, additional, Banna, Giuseppe Luigi, additional, Grassi, Luigi, additional, Mego, Michal, additional, and De Giorgi, Ugo, additional

Published
2019
Full Text
View/download PDF

65. Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC).

Author

Conteduca, Vincenza, primary, Wetterskog, Daniel, additional, Scarpi, Emanuela, additional, Romanel, Alessandro, additional, Gurioli, Giorgia, additional, Jayaram, Anuradha, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Casadei, Chiara, additional, Menna, Cecilia, additional, Wingate, Anna, additional, Demichelis, Francesca, additional, De Giorgi, Ugo, additional, and Attard, Gerhardt, additional

Published
2019
Full Text
View/download PDF

66. Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management

Author

Casadei, Chiara, primary, Schepisi, Giuseppe, additional, Menna, Cecilia, additional, Chovanec, Michal, additional, Gurioli, Giorgia, additional, Gallà, Valentina, additional, Altavilla, Amelia, additional, Marcellini, Massimo, additional, Bellia, Salvatore Roberto, additional, Lolli, Cristian, additional, Mego, Michal, additional, Rosti, Giovanni, additional, and De Giorgi, Ugo, additional

Published
2019
Full Text
View/download PDF

67. Psychosocial Issues in Long-Term Survivors of Testicular Cancer

Author

Schepisi, Giuseppe, primary, De Padova, Silvia, additional, De Lisi, Delia, additional, Casadei, Chiara, additional, Meggiolaro, Elena, additional, Ruffilli, Federica, additional, Rosti, Giovanni, additional, Lolli, Cristian, additional, Ravaglia, Giorgia, additional, Conteduca, Vincenza, additional, Farolfi, Alberto, additional, Grassi, Luigi, additional, and De Giorgi, Ugo, additional

Published
2019
Full Text
View/download PDF

70. Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC).

Author

Conteduca, Vincenza, primary, Jayaram, Anuradha, additional, Romero-Laorden, Nuria, additional, Wetterskog, Daniel, additional, Salvi, Samanta, additional, Gurioli, Giorgia, additional, Scarpi, Emanuela, additional, Castro, Elena, additional, Marin, Mercedes, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Wingate, Anna, additional, Medina, Ana, additional, Fornarini, Giuseppe, additional, Basso, Umberto, additional, Mellado, Begona, additional, Gonzalez-Billalabeitia, Enrique, additional, Olmos, David, additional, Attard, Gerhardt, additional, and De Giorgi, Ugo, additional

Published
2018
Full Text
View/download PDF

72. Immunotherapy for Prostate Cancer: Where We Are Headed

Author

Schepisi, Giuseppe, primary, Farolfi, Alberto, additional, Conteduca, Vincenza, additional, Martignano, Filippo, additional, De Lisi, Delia, additional, Ravaglia, Giorgia, additional, Rossi, Lorena, additional, Menna, Cecilia, additional, Bellia, Salvatore, additional, Barone, Domenico, additional, Gunelli, Roberta, additional, and De Giorgi, Ugo, additional

Published
2017
Full Text
View/download PDF

74. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone

Author

Conteduca, Vincenza, primary, Caffo, Orazio, additional, Lolli, Cristian, additional, Aieta, Michele, additional, Scarpi, Emanuela, additional, Bianchi, Emanuela, additional, Maines, Francesca, additional, Schepisi, Giuseppe, additional, Salvi, Samanta, additional, Massari, Francesco, additional, Carrozza, Francesco, additional, Veccia, Antonello, additional, Chiuri, Vincenzo E., additional, Campadelli, Enrico, additional, Facchini, Gaetano, additional, and De Giorgi, Ugo, additional

Published
2017
Full Text
View/download PDF

75. Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide.

Author

Conteduca, Vincenza, primary, Salvi, Samanta, additional, Casadio, Valentina, additional, Lolli, Cristian, additional, Gurioli, Giorgia, additional, Schepisi, Giuseppe, additional, Martignano, Filippo, additional, Menna, Cecilia, additional, Burgio, Salvatore Luca, additional, Testoni, Sara, additional, Attard, Gerhardt, additional, and De Giorgi, Ugo, additional

Published
2017
Full Text
View/download PDF

76. Vitamin D status among long-term survivors of testicular cancer

Author

Schepisi, Giuseppe, primary, De Padova, Silvia, additional, Scarpi, Emanuela, additional, Lolli, Cristian, additional, Gurioli, Giorgia, additional, Menna, Cecilia, additional, Burgio, Salvatore L., additional, Rossi, Lorena, additional, Gallà, Valentina, additional, Casadio, Valentina, additional, Salvi, Samanta, additional, Conteduca, Vincenza, additional, and De Giorgi, Ugo, additional

Published
2016
Full Text
View/download PDF

77. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review

Author

Romano, Francesco Jacopo, primary, Rossetti, Sabrina, additional, Conteduca, Vincenza, additional, Schepisi, Giuseppe, additional, Cavaliere, Carla, additional, Franco, Rossella Di, additional, Mantia, Elvira La, additional, Castaldo, Luigi, additional, Nocerino, Flavia, additional, Ametrano, Gianluca, additional, Cappuccio, Francesca, additional, Malzone, Gabriella, additional, Montanari, Micaela, additional, Vanacore, Daniela, additional, Quagliariello, Vincenzo, additional, Piscitelli, Raffaele, additional, Pepe, Maria Filomena, additional, Berretta, Massimiliano, additional, D'Aniello, Carmine, additional, Perdonà, Sisto, additional, Muto, Paolo, additional, Botti, Gerardo, additional, Ciliberto, Gennaro, additional, Veneziani, Bianca Maria, additional, Falco, Francesco De, additional, Maiolino, Piera, additional, Caraglia, Michele, additional, Montella, Maurizio, additional, Giorgi, Ugo De, additional, and Facchini, Gaetano, additional

Published
2016
Full Text
View/download PDF

79. Circulating AR copy number and outcome to enzalutamide in patients with metastatic castration-resistant prostate cancer after docetaxel.

Author

Salvi, Samanta, primary, Casadio, Valentina, additional, Conteduca, Vincenza, additional, Lolli, Cristian, additional, Gurioli, Giorgia, additional, Martignano, Filippo, additional, Schepisi, Giuseppe, additional, Testoni, Sara, additional, Scarpi, Emanuela, additional, Amadori, Dino, additional, Calistri, Daniele, additional, Attard, Gerhardt, additional, and De Giorgi, Ugo, additional

Published
2016
Full Text
View/download PDF

80. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer

Author

Salvi, Samanta, primary, Casadio, Valentina, additional, Conteduca, Vincenza, additional, Lolli, Cristian, additional, Gurioli, Giorgia, additional, Martignano, Filippo, additional, Schepisi, Giuseppe, additional, Testoni, Sara, additional, Scarpi, Emanuela, additional, Amadori, Dino, additional, Calistri, Daniele, additional, Attard, Gerhardt, additional, and Giorgi, Ugo De, additional

Published
2016
Full Text
View/download PDF

83. Taxane-related nail toxicity

Author

Schepisi, Giuseppe, primary, Conteduca, Vincenza, additional, Lolli, Cristian, additional, Medri, Matelda, additional, and De Giorgi, Ugo, additional

Published
2015
Full Text
View/download PDF

84. Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.

Author

De Giorgi, Ugo, primary, Maruzzo, Marco, additional, Santoni, Matteo, additional, Massari, Francesco, additional, Wheater, Matthew James, additional, Scarpi, Emanuela, additional, Lolli, Cristian, additional, Sotte, Valeria, additional, Crabb, Simon J., additional, Cascinu, Stefano, additional, Basso, Umberto, additional, and Schepisi, Giuseppe, additional

Published
2015
Full Text
View/download PDF

85. ARCopy Number and ARSignaling-directed Therapies in Castration-resistant Prostate Cancer

Author

Salvi, Samanta, Conteduca, Vincenza, Lolli, Cristian, Testoni, Sara, Casadio, Valentina, Zaccheroni, Andrea, Rossi, Lorena, Burgio, Salvatore L., Menna, Cecilia, Schepisi, Giuseppe, and De Giorgi, Ugo

Abstract

Background: Adaptive upregulation of Androgen Receptor (AR) is the most common event involved in the progression from hormone sensitive to Castration-Resistant Prostate Cancer (CRPC). AR signaling remains the main target of new AR signalling-directed therapies such as abiraterone and enzalutamide in CRPC patients. Objective: In this review, we discuss general mechanisms of resistance to AR-targeted therapies, with a focus on the role of AR Copy Number (CN). We reported methods and clinical applications of AR CN evaluation in tissue and liquid biopsy, thus to have a complete information regarding its role as predictive and prognostic biomarker. Conclusion: Outcomes of CRPC patients are reported to be highly variable as the consequence of tumor heterogeneity. AR CN could contribute to patient selection and tumor monitoring in CRPC treated with new anti-cancer treatment as abiraterone and enzalutamide. Further studies to investigate AR CN effect to these agents and its potential combination with other prognostic or predictive clinical factors are necessary in the context of harmonized clinical trial design.

Published
2018
Full Text
View/download PDF

88. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review

Author

Maria Filomena Pepe, Elvira La Mantia, Gabriella Malzone, Flavia Nocerino, Gianluca Ametrano, Vincenzo Quagliariello, Sisto Perdonà, Gennaro Ciliberto, Sabrina Rossetti, Gerardo Botti, Bianca Maria Veneziani, Francesco De Falco, Ugo De Giorgi, Luigi Castaldo, Gaetano Facchini, Daniela Vanacore, Micaela Montanari, Rossella Di Franco, Carmine D'Aniello, Carla Cavaliere, Francesco Jacopo Romano, Raffaele Piscitelli, Michele Caraglia, Francesca Cappuccio, Vincenza Conteduca, Paolo Muto, Giuseppe Schepisi, Piera Maiolino, Massimiliano Berretta, Maurizio Montella, Romano, Francesco Jacopo, Rossetti, Sabrina, Conteduca, Vincenza, Schepisi, Giuseppe, Cavaliere, Carla, Di Franco, Rossella, Lamantia, Elvira, Castaldo, Luigi, Nocerino, Flavia, Ametrano, Gianluca, Cappuccio, Francesca, Malzone, Gabriella, Montanari, Micaela, Vanacore, Daniela, Quagliariello, Vincenzo, Piscitelli, Raffaele, Pepe, Maria Filomena, Berretta, Massimiliano, D'Aniello, Carmine, Perdonà, Sisto, Muto, Paolo, Botti, Gerardo, Ciliberto, Gennaro, Veneziani, BIANCA MARIA, De Falco, Francesco, Maiolino, Piera, Caraglia, Michele, Montella, Maurizio, De Giorgi, Ugo, Facchini, Gaetano, La Mantia, Elvira, and Veneziani, Bianca Maria

Subjects
Male, p53, 0301 basic medicine, DNA Repair, Review, Poly(ADP-ribose) Polymerase Inhibitors, testis, DDR, 03 medical and health sciences, 0302 clinical medicine, Testicular Neoplasms, Radiation oncology, Animals, Humans, Medicine, ATM, Germ cell cancer, P53, Testis, Testicular Germ Cell Cancer, germ cell cancer, business.industry, Advanced stage, Proto-Oncogene Proteins c-mdm2, Neoplasms, Germ Cell and Embryonal, DNA Damage Repair, Gene Expression Regulation, Neoplastic, Clinical Practice, General pathology, 030104 developmental biology, Testi, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cisplatin, Tumor Suppressor Protein p53, Homologous Recombination Deficiency, business, Humanities, DNA Damage, Signal Transduction
Abstract

// Francesco Jacopo Romano 1 , Sabrina Rossetti 1,2 , Vincenza Conteduca 3 , Giuseppe Schepisi 3 , Carla Cavaliere 1,4 , Rossella Di Franco 1,5 , Elvira La Mantia 1,6 , Luigi Castaldo 1,7 , Flavia Nocerino 8 , Gianluca Ametrano 1,5 , Francesca Cappuccio 1,9 , Gabriella Malzone 1,6 , Micaela Montanari 1,10 , Daniela Vanacore 1 , Vincenzo Quagliariello 1 , Raffaele Piscitelli 1,11 , Maria Filomena Pepe 1,6 , Massimiliano Berretta 12 , Carmine D’Aniello 1,13 , Sisto Perdona 7 , Paolo Muto 5 , Gerardo Botti 6 , Gennaro Ciliberto 14 , Bianca Maria Veneziani 10 , Francesco De Falco 9 , Piera Maiolino 11 , Michele Caraglia 15 , Maurizio Montella 8 , Ugo De Giorgi 3 and Gaetano Facchini 1,2 1 Progetto ONCONET2.0, Linea Progettuale 14 per L’implementazione della Prevenzione e Diagnosi Precoce del Tumore alla Prostata e Testicolo, Regione Campania, Italy 2 Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori ‘Fondazione G. Pascale’, IRCCS, Naples, Italy 3 Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy 4 Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto, Taranto, Italy 5 Radiation Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’, IRCCS, Napoli, Italy 6 Pathology Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, Naples, Italy 7 Department of Uro-Gynaecological Oncology, Division of Urology, Istituto Nazionale Tumori ‘Fondazione G. Pascale’, IRCCS, Naples, Italy 8 Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’, IRCCS, Napoli, Italy 9 Psicology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’, IRCCS, Napoli, Italy 10 Department of Molecular Medicine and Medical Biotechnologies, University of Naples “Federico II”, Naples, Italy 11 Pharmacy Unit, Istituto Nazionale Tumori, Istituto Nazionale Tumori-Fondazione G. Pascale Naples, Italy 12 Department of Medical Oncology, CRO Aviano, National Cancer Institute, Aviano, Italy 13 Division of Medical Oncology, A.O.R.N. dei COLLI “Ospedali Monaldi-Cotugno-CTO”, Napoli, Italy 14 Scientific Directorate, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’, IRCCS, Napoli, Italy 15 Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy Correspondence to: Francesco Jacopo Romano, email: // Keywords : testis; germ cell cancer; DDR; ATM; p53 Received : September 12, 2016 Accepted : October 19, 2016 Published : November 03, 2016 Abstract Notwithstanding the peculiar sensitivity to cisplatin-based treatment, resulting in a very high percentage of cures even in advanced stages of the disease, still we do not know the biological mechanisms that make Testicular Germ Cell Tumor (TGCT) “unique” in the oncology scene. p53 and MDM2 seem to play a pivotal role, according to several in vitro observations, but no correlation has been found between their mutational or expression status in tissue samples and patients clinical outcome. Furthermore, other players seem to be on stage: DNA Damage Repair Machinery (DDR) , especially Homologous Recombination (HR) proteins, above all Ataxia Telangiectasia Mutated (ATM), cooperates with p53 in response to DNA damage, activating apoptotic cascade and contributing to cell “fate”. Homologous Recombination deficiency has been assumed to be a Germ Cell Tumor characteristic underlying platinum-sensitivity , whereby Poly(ADP-ribose) polymerase (PARP), an enzyme involved in HR DNA repair, is an intriguing target: PARP inhibitors have already entered in clinical practice of other malignancies and trials are recruiting TGCT patients in order to validate their role in this disease. This paper aims to summarize evidence, trying to outline an overview of DDR implications not only in TGCT curability, but also in resistance to chemotherapy.

Published
2016
Full Text
View/download PDF

89. An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Author

Serra R, Giunta EF, Schepisi G, Brighi N, Montanari D, Lolli C, Bleve S, Piras M, Palmieri G, Scartozzi M, Paliogiannis P, and De Giorgi U

Abstract

Introduction: Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) polymerase inhibitors (PARPis)., Areas Covered: This review evaluates the clinical efficacy, safety, and future potential of combining talazoparib, a potent PARPi, with enzalutamide, a strong androgen receptor (AR) antagonist. The combination of these two drugs was evaluated by the TALAPRO-2 trial, demonstrating significant improvement in radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients, particularly those with Homologous Recombination Repair (HRR) gene mutations such as BRCA1/2., Expert Opinion: Emerging biomarkers like TMPRSS2-ERG and RB1 gene mutations have been recently reported as potential predictors of clinical outcome in the TALAPRO-2 all-comers population. Genomic markers for homologous recombination deficiency (HRD) are other potential drivers of response to PARPi/ARPI combination. Further investigation is needed to refine treatment strategies, including targeting non-HRR mutations, and to expand the role of this combination therapy in earlier stages of prostate cancer.

Published
2024
Full Text
View/download PDF

90. Vitamin D status among long-term survivors of testicular cancer.

Author

Schepisi G, De Padova S, Scarpi E, Lolli C, Gurioli G, Menna C, Burgio SL, Rossi L, Gallà V, Casadio V, Salvi S, Conteduca V, and De Giorgi U

Subjects
Adult, Aged, Biomarkers, Case-Control Studies, Combined Modality Therapy, Comorbidity, Humans, Male, Middle Aged, Neoplasm Staging, Neoplasms, Germ Cell and Embryonal blood, Neoplasms, Germ Cell and Embryonal diagnosis, Neoplasms, Germ Cell and Embryonal mortality, Neoplasms, Germ Cell and Embryonal therapy, Risk Factors, Testicular Neoplasms diagnosis, Testicular Neoplasms therapy, Young Adult, Cancer Survivors, Testicular Neoplasms blood, Testicular Neoplasms mortality, Vitamin D blood
Abstract

A correlation between disturbances in hormone levels and the onset of metabolic disorders has been reported in long-term survivors of testicular cancer (TC).We evaluated serum vitamin D levels and other biological parameters in a consecutive series of 61 long-term (≥3 years) unilateral TC survivors with a median a follow-up of 4 years and in a cohort of healthy males. Deficient vitamin D levels were observed in 10 (17%) of the 58 long-term unilateral TC survivors but were not reported in healthy males (p=.019, Fisher test). Median vitamin D levels were 18.6 ug/L in 58 assessable TC survivors and 23.6 ug/L in 40 healthy males (p=.031). In univariate logistic regression analysis, TC diagnosis was associated with inadequate levels of vitamin D (p=.047). Vitamin D levels were lower when follow-up was > 10 years, albeit this difference was not statistically significant (p=.074). Long-term (especially > 10 years) TC survivors may have difficulty maintaining optimal vitamin D levels. Larger studies are needed to better characterize vitamin D status and possible correlations with premature hormonal aging reported in long-term TC survivors.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results